For research use only. Not for therapeutic Use.
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) [1][2].
Dulaglutide (50 nM and 100 nM; 24 h) ameliorates ox-LDL-induced oxidative stress and suppresses ox-LDL-induced mitochondrial dysfunction in human aortic endothelial cells (HAECs)[1].
Dulaglutide (0, 0.05, 0.5, 1.5, or 5 mg/kg; s.c.; twice week, for 93 weeks) increases the incidence of thyroid C-cell hyperplasia and neoplasia in the rat carcinogenicity study[2].
| Catalog Number | I046317 |
| CAS Number | 923950-08-7 |
| Purity | ≥95% |
| Reference | [1]. Chang W, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019 Dec;116:73-79. [2]. Hertzel C Gerstein, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet [3]. Byrd RA, et al. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor AgonistDulaglutide in Rodents. Endocrinology. 2015 Jul;156(7):2417-28. |
